Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15422779 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422684 | 0.92 | SLC6A3 (0.85) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422503 | 0.92 | SLC6A3 (0.85) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422510 | 0.89 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422073 | 0.89 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL17445262 | 0.89 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422663 | 0.89 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422275 | 0.85 | SLC6A4 (0.92) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422775 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15422265 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797870-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING 1-[1-PHENYL-CYCLOBUTYL]ISOBUTYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Revivia Pharmaceuticals, Inc. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9695116-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-04-28 | — | — | US | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | SLC6A4 26/4885SLC6A3 58/4885SLC6A2 65/4885 |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | PNMT, HTR6, COMT | SLC6A4 26/4885SLC6A3 58/4885SLC6A2 65/4885 |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | SLC6A4 26/4885SLC6A3 58/4885SLC6A2 65/4885 |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | SLC6A4 26/4885SLC6A3 58/4885SLC6A2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.